China Resources Pharma completes RMB3bn bond issuance

China Resources Pharmaceutical Group Limited (HKEX:3320) has announced the completion of the public issuance of the third tranche of its 2025 corporate bonds in the People's Republic of China. The bonds, issued through the company's non-wholly-owned subsidiary, CR Pharmaceutical Commercial, total RMB3 billion in aggregate principal amount. The bonds have a term of three years and carry a coupon rate of 1.82% per annum. The net proceeds from the issuance will be used to repay interest-bearing debt. The announcement references previous announcements on January 15, 2025, and April 24, 2025, regarding prior tranches of the 2025 corporate bonds. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.